Activating monocyte/neutrophil TREM1 with the agonistic antibody PY159 (IgG1) enhances co-stimulatory molecule expression and IFNγ responses to support anti-tumour immunity [139], but TREM1 is also associated with poor prognosis and inflammation-related carcinogenesis [139, 141]. The gene discussed is TREM1; the disease is neoplasm.